Over a 4% year period, 1,940 asymptomatic men were entered in a prostate cancer detection program consisting of digital rectal examination (DRE), prostate-specific antigen (PSA), and transrectal prostate ultrasound (TRUS). Four hundred and sixteen biopsies were performed resulting in the diagnosis o
Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4–10
✍ Scribed by L. Martínez-Piñeiro; J. M. García Mediero; P. González Gancedo; A. Tabernero; D. Lozano; J. J. López-Tello; J. M. Alonso-Dorrego; C. Núñez; M. L. Picazo; R. Madero; J. J. De La Peña
- Publisher
- Springer-Verlag
- Year
- 2004
- Tongue
- English
- Weight
- 337 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In a aptient population, coordinated use of digital rectal examination and prostate-specific antigen can alert the physician as to the possible existence of prostate cancer. If both are used as first-line studies, abnormality of either can then direct the need for further study by transrectal ultras
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite ´, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie
Molecular forms of prostate-specific antigen (PSA) improve the differentiation between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) in men with total PSA concentrations between 4 and 10 microg/l. To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identi
## Abstract Prostate‐specific antigen (PSA) dynamics have been proposed to predict outcome in men with prostate cancer. We assessed the value of PSA velocity (PSAV) and PSA doubling time (PSADT) for predicting prostate cancer‐specific mortality (PCSM) in men with clinically localized prostate cance